Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Vertex Pharmaceuticals Incorporated : Trump's Pick to Lead FDA Has Backing of Big Pharma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2017 | 01:45pm CEST
By Joseph Walker 

Scott Gottlieb, the veteran health-care investor and physician nominated to lead the U.S. Food and Drug Administration, has strong backing from the pharmaceuticals industry as he prepares to put his stamp on the agency.

The Senate is expected to conduct a final vote as soon as this week to confirm Dr. Gottlieb's appointment as FDA commissioner.

Dr. Gottlieb is well known by many drug-industry executives. He worked for years as a consultant to companies including GlaxoSmithKline PLC and Vertex Pharmaceuticals Inc., spoke frequently at health-care and investor conferences, and wrote hundreds of essays and op-eds, often advocating for the FDA to approve drugs faster and loosen regulations on off-label marketing.

Dr. Gottlieb favors free-market strategies to bring down drug costs, including by increasing the rate of generic drug approvals at the FDA. He has also questioned the wisdom of allowing U.S. consumers to import brand-name drugs from countries like Canada, where they cost less, in part because of safety concerns -- a viewpoint shared by drugmakers.

"He agrees with the basic concept of the pharmaceutical industry: the need to have drugs come to market quickly, viewing the bureaucracy as necessary but [it] can get in the way of innovation," says Ronny Gal, a stock analyst at Sanford C. Bernstein & Co.

Company officials say they expect Dr. Gottlieb to push the FDA to accelerate its adoption of more-flexible approaches to evaluating new drugs and clinical trials. His experience as a physician and senior FDA official during the George W. Bush administration should help him garner support from the agency's rank-and-file staff to implement his agenda, executives say.

He "sounds like a progressive person who wants to get things done," said Eli Lilly & Co. Chief Executive David Ricks in an interview. "He's got experience in the agency already. He's a doctor and a cancer survivor. Sounds to me like he has a balanced perspective."

Dr. Gottlieb's extensive prior business relationships with pharmaceutical companies have spurred criticism from some Democrats and public advocacy groups. In April, five Senate Democrats questioned Dr. Gottlieb's commitment to fighting opioid addiction because of his work as a paid expert witness for a fentanyl-drug maker later acquired by Teva Pharmaceutical Industries Ltd. Public Citizen, a liberal watchdog group, said that Dr. Gottlieb was "entangled in an unprecedented web of close financial and business ties to the pharmaceutical industry."

Dr. Gottlieb has said he would recuse himself for one year from FDA decisions on more than 20 companies where he has potential conflicts of interest. "I understand how important impartiality of this agency is," Dr. Gottlieb said at his Senate confirmation hearing in April. "I don't want to do anything in my conduct to reduce people's confidence in the agency's mission."

Dr. Gottlieb earned at least $645,000 from drug companies and trade groups from the beginning of 2016 through the first two months of 2017, according to his disclosure statements.

He served for seven years on a GlaxoSmithKline board that manages the company's research and development investments, providing "a valuable perspective on the U.S. health-care and payer environment," said a GSK spokeswoman. As FDA commissioner, Dr. Gottlieb "will help ensure that the FDA maintains its focus on innovation and protecting public health by expeditiously approving safe and effective new treatments for patients," she said.

Dr. Gottlieb has also been supportive of loosening FDA restrictions on off-label marketing, where companies advertise uses for their drugs that haven't been cleared by the agency. He has advocated allowing companies to distribute such information to doctors so long as it is truthful and non-misleading.

There are numerous alternatives to "FDA's current regime -- which virtually bans off-label promotion -- that would promote FDA's public health goals even better than the current regime does," Dr. Gottlieb wrote in expert testimony in 2015 on behalf of Amarin Corp., in a lawsuit the company filed against the FDA over its off-label marketing policies.

Like other of President Donald Trump's nominees, Dr. Gottlieb has been critical of the agency he is nominated to oversee. He wrote in a 2012 essay that the FDA has a "harmful culture" that mistrusts doctors to prescribe drugs appropriately, leading officials to have "an excessive desire for certainty" that new medicines are safe and effective before they are approved, he wrote.

The FDA has several methods for accelerating approvals, such as granting conditional approval if studies show the drug is "reasonably likely" to help patients live longer or have other benefits. Some FDA divisions have embraced the faster methods, but other divisions are still very "rigid," says Ron Cohen, chief executive of Acorda Therapeutics Inc. "Even if you bring them evidence of benefit to patients, it's still an uphill climb."

Dr. Gottlieb said in April that he would create "consistency to how different parts of the FDA" use their powers.

Some researchers question how much further the FDA can go in speeding up drug approvals without lowering its standards. More than two-thirds of drug approvals last year were completed under "priority review," where the FDA makes an approval decision within six months instead of the standard 10 months, according to the FDA.

"The FDA is already one of the fastest regulatory agencies in the world, " says Aaron Kesselheim, an associate professor of medicine at Harvard Medical School. "Faster for faster's sake is not wise."

--Peter Loftus contributed to this article.

Write to Joseph Walker at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -3.42% 1412.2 Delayed Quote.10.56%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
04/24VERTEX PHARMACEUTICALS : and NHS close in on cystic fibrosis drug pricing deal
AQ
04/24VERTEX PHARMACEUTICALS : UK Ministers call on Vertex to speed up price negotiati..
AQ
04/23VERTEX PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on Apr..
AQ
04/17VERTEX PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on Apr..
BU
04/10VERTEX PHARMACEUTICALS : Mass. governor defends Vertex drug pricing, saying inno..
AQ
04/09VERTEX PHARMACEUTICALS : New York to consider further Medicaid rebates on Orkamb..
AQ
04/03VERTEX PHARMACEUTICALS : Appoints Kimberly A. White as Senior Vice President and..
AQ
03/29VERTEX PHARMACEUTICALS : Appoints Kimberly A. White as Senior Vice President and..
BU
03/20VERTEX PHARMACEUTICALS : MPs call on U.K. government to resolve Orkambi impasse
AQ
03/13MANAGEMENT TRACKS : WuXi NextCode, Assembly
AQ
More news
News from SeekingAlpha
04/25Notable earnings after Thursday?s close 
04/20Key events next week - healthcare 
04/14VENTURE CAPITAL DEALS OF THE WEEK : Tencent Led $3B Investment 
04/13Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned 
04/09THE BIO-TECH 'WRECK' : General, And Company-Specific Analysis 
Financials ($)
Sales 2018 2 794 M
EBIT 2018 816 M
Net income 2018 448 M
Finance 2018 2 398 M
Yield 2018 -
P/E ratio 2018 88,22
P/E ratio 2019 46,83
EV / Sales 2018 13,3x
EV / Sales 2019 10,5x
Capitalization 39 523 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 192 $
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS3.88%39 523
GILEAD SCIENCES3.31%96 498
REGENERON PHARMACEUTICALS-15.95%34 033
GENMAB20.17%12 599
BEIGENE LTD (ADR)73.75%9 087
BLUEBIRD BIO INC-8.70%8 410